We have located links that may give you full text access.
Bacterial sepsis after prostate biopsy--a new perspective.
Urology 2009 December
OBJECTIVES: To determine the incidence of sepsis following transrectal ultrasound (TRUS)-guided prostate biopsy at our center.
METHODS: We retrospectively reviewed a group of 24 men who presented with urosepsis after undergoing TRUS biopsy at our center.
RESULTS: Of the 24 men, 22 were given prophylactic ciprofloxacin. The median time to presentation of sepsis was 1 day after biopsy. The median length of hospitalization was 4 days. Escherichia coli was the most frequent cause of urosepsis (67%). Variable resistance patterns were observed. Enterobacter cloacae and Streptococcus viridans were isolated in 2 cases. No bacteria were isolated in 6 cases. Two patients who received extensive antibiotic prophylaxis still developed urosepsis. Treatment of patients infected with multiresistant anaerobic strains using metronidazole among others, proved successful. High sensitivities toward cefazolin, gentamicin, and tobramycin were observed. The number of cases reported was likely an underestimation, because some patients may have reported to other hospitals and were not captured by this study. In addition, some patients may not have developed infection and urosepsis despite harboring ciprofloxacin-resistant bacteria.
CONCLUSIONS: Prophylactic ciprofloxacin is still a useful option for the prevention of urosepsis after TRUS biopsy, as the incidence is relatively low. For the patient who develops urosepsis after TRUS biopsy, ciprofloxacin resistance needs to be suspected and the treatment regime should be tailored to the resistance profiles of the local region, the patient's medical history, and the culture and sensitivity reports.
METHODS: We retrospectively reviewed a group of 24 men who presented with urosepsis after undergoing TRUS biopsy at our center.
RESULTS: Of the 24 men, 22 were given prophylactic ciprofloxacin. The median time to presentation of sepsis was 1 day after biopsy. The median length of hospitalization was 4 days. Escherichia coli was the most frequent cause of urosepsis (67%). Variable resistance patterns were observed. Enterobacter cloacae and Streptococcus viridans were isolated in 2 cases. No bacteria were isolated in 6 cases. Two patients who received extensive antibiotic prophylaxis still developed urosepsis. Treatment of patients infected with multiresistant anaerobic strains using metronidazole among others, proved successful. High sensitivities toward cefazolin, gentamicin, and tobramycin were observed. The number of cases reported was likely an underestimation, because some patients may have reported to other hospitals and were not captured by this study. In addition, some patients may not have developed infection and urosepsis despite harboring ciprofloxacin-resistant bacteria.
CONCLUSIONS: Prophylactic ciprofloxacin is still a useful option for the prevention of urosepsis after TRUS biopsy, as the incidence is relatively low. For the patient who develops urosepsis after TRUS biopsy, ciprofloxacin resistance needs to be suspected and the treatment regime should be tailored to the resistance profiles of the local region, the patient's medical history, and the culture and sensitivity reports.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app